On November 6, 2018, the Securities and Exchange Commission announced that Allergan Therapeutics, Inc. ("Aclaris"), a biopharmaceutical company based in New York City, announced that it has agreed to acquire Allergan for $1.6 billion.  According to the SEC's complaint filed in the U.S. District Court for the Southern District of New York, Allergan's acquisition of Allergan is subject to court approval.  The SEC's complaint alleges that Allergan's acquisition of Allergan, which is developing a topical topical treatment for the treatment of dermatitis, enabled Allergan to acquire Allergan for $1.7 billion in cash and investments.  The complaint alleges that Allergan's stock price increased significantly in the second half of 2018, and Allergan's stock price increased substantially in the third quarter.  The SEC's complaint, filed in the U.S. District Court, charges Allergan with violating the antifraud provisions of Section 17(a) of the Securities Act of 1933 and Section 10(b) of the Securities Exchange Act of 1934 and Rule 10b-5 thereunder.  Without admitting or denying the allegations in the complaint, Allergan has agreed to pay $1.6 billion in disgorgement and prejudgment interest and to pay a civil penalty of $1.6 million.  The settlement is subject to court approval.  The SEC appreciates the assistance of the U.S. Attorney's Office for the Southern District of New York, the Federal Bureau of Investigation, and the U.S. Secret Service.  The SEC's Office of Investor Education and Advocacy has issued anÂ Investor AlertÂ to encourage investors to check the background of anyone selling or offering them an investment using the free and simple search tool onÂ Investor.gov.  The SEC's Office of Investor Education has also issued an Investor AlertÂ to encourage investors toÂ check the background of anyone selling or offering an investment usingÂ Investor.gov.